一项双盲、随机、假对照、单中心光生物调节治疗干性年龄相关性黄斑变性的研究
LIGHTSITE I 研究在30例(46眼)干性年龄相关性黄斑变性受试者中评估光生物调节(PBM)的疗效与安全性,受试者接受Valeda光递送系统治疗,1年内完成两个疗程(每周3次,持续3-4周)。PBM组在M1和M7每个疗程后最佳矫正视力平均字母得分增加4个字母,M1时约50%的PBM受试者改善≥5个字母,假治疗组为13.6%;对比敏感度、中心玻璃膜疣体积、中心玻璃膜疣厚度和生活质量均有统计学显著改善(P<0.05),未报告器械相关不良事件。
要点
- PBM组每个疗程后最佳矫正视力平均增加4个字母,M1时约50%受试者改善≥5个字母。
- 高应答者(≥5字母改善)在初始治疗后增加8个字母(P<0.01),且处于更早期AMD阶段。
- 对比敏感度、中心玻璃膜疣体积、中心玻璃膜疣厚度和生活质量均有统计学显著改善(P<0.05)。
核心结论
- PBM治疗在统计学上改善了临床和解剖学结局,在更早期干性AMD受试者中观察到更显著获益。
- 需要重复PBM治疗以维持获益。
- 这些先导性发现支持既往报告,并提示PBM作为干性AMD受试者安全有效治疗手段的效用。
研究设计与样本
- 双盲、随机、假对照、单中心研究,共30例(46眼)干性年龄相关性黄斑变性受试者。
- 受试者接受Valeda光递送系统治疗,1年内完成两个疗程(每周3次,持续3-4周)。
主要发现
- PBM组在M1和M7每个疗程后最佳矫正视力平均字母得分增加4个字母。
- M1时约50%的PBM受试者改善≥5个字母,假治疗组为13.6%。
- PBM组高应答者(≥5字母改善)初始治疗后增加8个字母(P<0.01),且处于更早期AMD阶段。
- 对比敏感度、中心玻璃膜疣体积、中心玻璃膜疣厚度和生活质量均有统计学显著改善(P<0.05)。
- 未报告器械相关不良事件。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The LIGHTSITE I study investigated the efficacy and safety of photobiomodulation (PBM) treatment in subjects with dry age-related macular degeneration. METHODS: Thirty subjects (46 eyes) were treated with the Valeda Light Delivery System, wherein subjects underwent two series of treatments (3× per week for 3-4 weeks) over 1 year. Outcome measures included best-corrected visual acuity, contrast sensitivity, microperimetry, central drusen volume and drusen thickness, and quality of life assessments. RESULTS: Photobiomodulation-treated subjects showed a best-corrected visual acuity mean letter score gain of 4 letters immediately after each treatment series at Month 1 (M1) and Month 7 (M7). Approximately 50% of PBM-treated subjects showed improvement of ≥5 letters versus 13.6% in sham-treated subjects at M1. High responding subjects (≥5-letter improvement) in the PBM-treated group showed a gain of 8 letters after initial treatment (P < 0.01) and exhibited earlier stages of age-related macular degeneration disease. Statistically significant improvements in contrast sensitivity, central drusen volume, central drusen thickness, and quality of life were observed (P < 0.05). No device-related adverse events were reported. CONCLUSION: Photobiomodulation treatment statistically improved clinical and anatomical outcomes with more robust benefits observed in subjects with earlier stages of dry age-related macular degeneration. Repeated PBM treatments are necessary to maintain benefits. These pilot findings support previous reports and suggest the utility of PBM as a safe and effective therapy in subjects with dry age-related macular degeneration.
引用
- Markowitz SN, Devenyi RG, Munk MR, et al. A DOUBLE-MASKED, RANDOMIZED, SHAM-CONTROLLED, SINGLE-CENTER STUDY WITH PHOTOBIOMODULATION FOR THE TREATMENT OF DRY AGE-RELATED MACULAR DEGENERATION. Retina. 2020. PMID: 31404033. doi:10.1097/IAE.0000000000002632
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。